TY  - JOUR
AU  - Sanković-Babić, Snežana
AU  - Kosanović, Rade
AU  - Ivanković, Zoran
AU  - Babac, Snezana
AU  - Tatović, Milica
PY  - 2014
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/1925
AB  - Introduction Over the last two decades the intratympanic perfusion of corticosteroids has been used as a minimally invasive surgical therapy of Meniere's disease. According to experimental studies the antiinflammatory, immunoprotective, antioxidant and neuroprotective role of the locally perfused corticosteroids was noticed in the inner ear structures. The recovery of action potentials in the cells of the Corti organ was confirmed as well as a decreased expression of aquaporine-1, a glycoprotein responsible for labyrinth hydrops and N and K ions derangement. Objective The study showed results of intratympanic perfusion therapy with dexamethasone in patients with retractable Meniere's disease who are resistant to conservative treatment. Methods Single doses of 4 mg/ml dexamethasone were given intratympanically in 19 patients with retractable Meniere's disease. Six single successive doses of dexamethasone were administered in the posteroinferior quadrant of the tympanic membrane. Follow-up of the patients was conducted by using a clinical questionnaire a month after completed perfusion series as well as on every third month up to one year. Results One month after completed first course of perfusions, in 78% of patients, vertigo problems completely ceased or were markedly reduced. The recovery of hearing function was recorded in 68% and marked tinnitus reduction in 84% of patients. After a year of follow-up, in 63% of patients the reduction of vertigo persisted, while hearing function was satisfactory in 52%. Tinitus reduction was present in 73% of patients. Conclusion Intratympanic perfusion of dexamethasone in patients with Meniere's disease is a minimally invasive therapeutic method that contributes to the reduction of the intensity of vertigo recurrent attacks, decrease of the intensity of tinnitus and improvement of the average hearing threshold. Patients with chronic diseases and Meniere's disease who are contraindicted for systemic administration of cortocosteroids (hypertension, diabetes, glaucoma, peptic ulcer, etc.) have an additional therapeutic option by dexamethasone intratympanic perfusion.
PB  - Srpsko lekarsko društvo, Beograd
T2  - Srpski arhiv za celokupno lekarstvo
T1  - Intratympanic Corticosteroid Perfusion in the Therapy of Meniere's Disease
VL  - 142
IS  - 5-6
SP  - 291
EP  - 295
DO  - 10.2298/SARH1406291S
ER  - 

@article{
author = "Sanković-Babić, Snežana and Kosanović, Rade and Ivanković, Zoran and Babac, Snezana and Tatović, Milica",
year = "2014",
abstract = "Introduction Over the last two decades the intratympanic perfusion of corticosteroids has been used as a minimally invasive surgical therapy of Meniere's disease. According to experimental studies the antiinflammatory, immunoprotective, antioxidant and neuroprotective role of the locally perfused corticosteroids was noticed in the inner ear structures. The recovery of action potentials in the cells of the Corti organ was confirmed as well as a decreased expression of aquaporine-1, a glycoprotein responsible for labyrinth hydrops and N and K ions derangement. Objective The study showed results of intratympanic perfusion therapy with dexamethasone in patients with retractable Meniere's disease who are resistant to conservative treatment. Methods Single doses of 4 mg/ml dexamethasone were given intratympanically in 19 patients with retractable Meniere's disease. Six single successive doses of dexamethasone were administered in the posteroinferior quadrant of the tympanic membrane. Follow-up of the patients was conducted by using a clinical questionnaire a month after completed perfusion series as well as on every third month up to one year. Results One month after completed first course of perfusions, in 78% of patients, vertigo problems completely ceased or were markedly reduced. The recovery of hearing function was recorded in 68% and marked tinnitus reduction in 84% of patients. After a year of follow-up, in 63% of patients the reduction of vertigo persisted, while hearing function was satisfactory in 52%. Tinitus reduction was present in 73% of patients. Conclusion Intratympanic perfusion of dexamethasone in patients with Meniere's disease is a minimally invasive therapeutic method that contributes to the reduction of the intensity of vertigo recurrent attacks, decrease of the intensity of tinnitus and improvement of the average hearing threshold. Patients with chronic diseases and Meniere's disease who are contraindicted for systemic administration of cortocosteroids (hypertension, diabetes, glaucoma, peptic ulcer, etc.) have an additional therapeutic option by dexamethasone intratympanic perfusion.",
publisher = "Srpsko lekarsko društvo, Beograd",
journal = "Srpski arhiv za celokupno lekarstvo",
title = "Intratympanic Corticosteroid Perfusion in the Therapy of Meniere's Disease",
volume = "142",
number = "5-6",
pages = "291-295",
doi = "10.2298/SARH1406291S"
}

Sanković-Babić, S., Kosanović, R., Ivanković, Z., Babac, S.,& Tatović, M.. (2014). Intratympanic Corticosteroid Perfusion in the Therapy of Meniere's Disease. in Srpski arhiv za celokupno lekarstvo
Srpsko lekarsko društvo, Beograd., 142(5-6), 291-295.
https://doi.org/10.2298/SARH1406291S

Sanković-Babić S, Kosanović R, Ivanković Z, Babac S, Tatović M. Intratympanic Corticosteroid Perfusion in the Therapy of Meniere's Disease. in Srpski arhiv za celokupno lekarstvo. 2014;142(5-6):291-295.
doi:10.2298/SARH1406291S .

Sanković-Babić, Snežana, Kosanović, Rade, Ivanković, Zoran, Babac, Snezana, Tatović, Milica, "Intratympanic Corticosteroid Perfusion in the Therapy of Meniere's Disease" in Srpski arhiv za celokupno lekarstvo, 142, no. 5-6 (2014):291-295,
https://doi.org/10.2298/SARH1406291S . .